SBBP - Strongbridge: Approved Drugs Near-Term Catalysts Still Not Convinced April, 22 2021 01:07 PM Strongbridge Biopharma plc SBBP has an approved product and a late-stage pipeline. However, Cushing's syndrome is a highly-differentiated market. Despite its positives, I'm not convinced about the long-term prospects of SBBP. For further details see: Strongbridge: Approved Drugs, Near-Term Catalysts, Still Not Convinced